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Purpose: Colchicine is commonly used in the manage-
ment of gout; however, older persons have higher risks
of toxicity. Accordingly, the Screening Tool of Older
Person’s potentially inappropriate Prescriptions (STOPP)
criteria for colchicine consider 43 months of treatment
as potentially inappropriate in older persons. Recent
evidence also suggests lower dosing of colchicine is as
effective and results in fewer toxicities than high-dose
colchicine. The objectives of this study were to determine
the dose, duration, and prescribers of colchicine and to
evaluate adherence to the STOPP criteria and interna-
tional guidelines for colchicine in older persons.
Methods: A retrospective, observational study was
conducted from April 1, 2006 to March 31, 2011 to
evaluate colchicine use. Nova Scotia Seniors’ Pharma-
care Program beneﬁciaries who met inclusion criteria
for an incident case of gout and who ﬁlled at least 1
prescription for colchicine during the study period
were included. Colchicine dose and duration were
reported descriptively. Multivariate logistic regression
was used to identify predictors of the study population
in making a claim for colchicine490 and4180 days.
Findings: A total of 518 persons were dispensed
1327 courses of colchicine during the study period.
The mean daily dose of colchicine ranged from 1.39 to
1.50 mg. Colchicine doses 41.2 mg were prescribed
in approximately one-third of the study population.*Current afﬁliation: Faculty of Medicine and Health Sciences,
Norwich Medical School, University of East Anglia, Norwich,
United Kingdom
†Current afﬁliation: Kent Drugs, Richibucto, New Brunswick,
Canada
October 2015Colchicine was prescribed for 490 days in 14.2% of
treatment courses and for 4180 days in 8.1% of
treatment courses. Female sex was the only predictor
of treatment duration 490 days.
Implications: This study is the ﬁrst to report on
colchicine dose and duration using STOPP criteria in a
speciﬁc cohort of older persons with incident gout.
Strategies to improve colchicine prescribing in older
persons are needed. (Clin Ther. 2015;37:2339–2346)
& 2015 The Authors. Published by Elsevier HS Journals,
Inc.
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persons.INTRODUCTION
Gout is common, with 2.7% of men and women
aged 419 years in the United States reporting a
diagnosis. Gout affects older persons more frequently.
The estimated lifetime prevalence of gout is lowest
(0.4%) in those aged 20 to 29 years and highest
(7.3%) in those aged 70 to 79 years.1
Colchicine is recommended as a ﬁrst-line alterna-
tive to nonsteroidal anti-inﬂammatory drugs in the
management of acute gout attacks and as prophylaxis
in combination with urate-lowering therapies (ULTs)
such as allopurinol.2,3 It substantially improvesAccepted for publication August 18, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.08.016
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Clinical Therapeuticspain and inﬂammation associated with acute attacks
compared with placebo.4,5 Colchicine was historically
dosed as 1 mg, followed by 0.5 mg every 2 hours until
complete response or toxicity.6 Nausea, vomiting, and
other adverse effects associated with this regimen were
reported,4,6 leading investigators to conclude that
lower dosing of colchicine may be waranteed.6
Evidence from 2010 suggests that low-dose colchicine
(1.8 mg over 1 hour) has similar efﬁcacy and less toxicity
than high-dose colchicine (4.8 mg over 6 hours) in
management of acute gout.5 Guidelines from the
American College of Rheumatology (ACR) published
in 2012 and the European League Against Rheumatism
(EULAR) published in 2006 recommend low-dose
colchicine (1.8 mg over 1 hour, followed 12 hours later
with 0.6 mg once or twice daily and 0.5 mg three times
daily, respectively) for acute gout attacks.2,3,7 When used
in combination with allopurinol for 3 to 6 months,8
colchicine prevents acute attacks of gout.3,8–12 The 2012
ACR guidelines provide the strongest recommendation
(evidence A) for continuation of colchicine for 6 months
after initiation of ULT3 with ULT continued as mono-
therapy indeﬁnitely.7
Older persons have higher risks of toxicity with
colchicine due to increasing rates of renal or hepatic
dysfunction.13 Older persons are also at increased risk
of serious adverse effects, including neuromuscular
toxicity and rhabdomyolysis.14 Polypharmacy may
also limit use of colchicine.13 Colchicine is a
cytochrome P450 3A4 and P-glycoprotein substrate.
Life-threatening and fatal interactions were reported
when used in combination with P-glycoprotein and
strong cytochrome P450 3A4 inhibitors.14
To minimize toxicity, the Screening Tool of Older
Persons’ potentially inappropriate Prescriptions (STOPP)
criteria were developed and validated with the use of a
Delphi consensus technique to provide prescribers with a
screening tool that consisted of 65 evidence-based criteria
for appraising older patients’ medications.15 The STOPP
criteria have provided guidelines for colchicine usage in
the management of gout.15 The initial version of the
STOPP criteria, published in 2008, indicated long-term
use of colchicine as a criterion for potentially inappro-
priate prescribing but did not specify duration.15
Although not available during the study period, revised
STOPP guidelines indicate potentially inappropriate
prescribing of colchicine for durations 43 months.16
The study objectives were to determine the dose
and duration of colchicine and to evaluate adherence2340to the STOPP criteria and international guidelines for
colchicine dispensed for Nova Scotia Seniors’ Phar-
macare Program (NSSPP) beneﬁciaries.
METHODS
This study examined trends in colchicine prescriptions
for NSSPP beneﬁciaries dispensed in Nova Scotia from
April 1, 2006 to March 31, 2011. The study was
approved by the Dalhousie University Research Ethics
Board reference number 2012-2657.
Study Population
The study population included all beneﬁciaries of
the NSSPP who met inclusion criteria for an incident
case of gout and who ﬁlled at least 1 prescription for
colchicine during the study period. Eligibility for the
NSSPP includes age Z65 years, permanent residency
status in Nova Scotia, and a valid health card with no
other current prescription drug coverage through a
private insurance provider.17 In 2010, NSSPP
provided beneﬁts to 68% of the population aged
Z65 years in Nova Scotia. In 2013 and 2014,
approximately 7.5% of NSSPP beneﬁciaries who
lived in long-term care homes were included in this
study (personal correspondence, Mike Joyce, MBA,
Director Health Economics, Government of Nova
Scotia).
Study Design and Data Collection
A retrospective observational methodology was
used. Data of NSSPP beneﬁciaries was accessed by
Health Data Nova Scotia in the Department of
Community Health and Epidemiology at Dalhousie
University. Potential incident cases of gout over the
period of April 1, 2006 to March 31, 2011 were
identiﬁed by excluding any individuals with a diag-
nosis of gout in the previous 5 years. Incident cases
also had to have at least 2 physician diagnosis for gout
in the physician visit administrative claims data (ICD9
274.xx or ICD10 M10.xx) at least 30 days apart
within a 12-month period. Other researchers have
used this algorithm to capture incident cases of
gout.18,19 A total of 2558 NSSPP beneﬁciaries were
identiﬁed with incident gout during the study period.
Colchicine was identiﬁed with the use of the Drug
Identiﬁcation Number and the World Health Organ-
ization, Anatomical Therapeutic Chemical classiﬁca-
tion 2014 M04AC01.20 For all colchicine users in our
cohort, we determined demographic characteristics ofVolume 37 Number 10
E. Black et al.beneﬁciaries, number of individuals prescribed
colchicine, the dose and duration of colchicine
prescriptions, and the type of physician (general
practitioner vs specialist) who diagnosed gout. For
each identiﬁed beneﬁciary who received colchicine, we
grouped individual prescriptions into treatment
courses on the basis of the start and end dates of
each prescription. The end date of the initial
prescription was calculated as the date the
prescription was dispensed plus the days supplied. If
the gap between the end of the initial prescription and
the start of the next prescription wasr14 days, it was
considered to be part of the same treatment course as
the previous prescription. If this gap was 414 days,
this prescription was taken to represent the start of a
new treatment course. Sensitivity analysis was
performed with a 30-day treatment gap and resulted
in similar patterns (data not shown). The prescribed
daily dose for each treatment course was calculated as
the total dose dispensed (quantity of drug dispensed 
strength of drug) divided by the total days dispensed
over a given treatment course. The aggregate days of
treatment within each course were categorized into the
following speciﬁc time periods: (1)r3 days, (2) 4 to 7
days, (3) 8 to 14 days, (4) 15 to 30 days, (5) 31 to 60
days, (6) 61 to 90 days, (7) 91 to 180 days, and
(8) 4180 days.
Kaplan-Meier survival curves were generated to
illustrate the proportion of beneﬁciaries by the dura-
tion of their treatment course for all patients having a
treatment course 47 days (n ¼ 417). Separate
survival curves were generated according to the
calendar year in which the treatment course began.
A single beneﬁciary could be represented by Z1
treatment courses contained within a single year,
spanning Z1 years, or multiple courses within/across
multiple years.
Data were analyzed to determine the number of
patients who received r1.2 mg/d, ≤1.5 mg/d, and
41.5 mg/d by calendar year (April 1, 2006 to March
31, 2011) to assess adherence to dosing recommen-
dations by the ACR and EULAR guidelines for
management of acute gout (beyond the ﬁrst day of
treatment) and chronic gout.4,7 Concordance for
prescribing of colchicine for prevention of acute
attacks during initiation of ULT with STOPP criteria
version 1 and the ACR guidelines was determined by
evaluating the number of patients who received a total
duration of r90 days, r180 days, and 4180 days.October 2015Statistical Analysis
Descriptive statistics were used to summarize NSSPP
beneﬁciaries by age categories and sex. The proportion of
beneﬁciaries who received at least 1 prescription for
colchicine in a ﬁscal year from April 1, 2006 to March
31, 2011 was divided into the following subpopulations:
(1) patient aged 65 to 69, 70 to 74, 75 to 79, 80 to 84,
and Z85 years; (2) patient sex; and (3) prescriber
specialty (general practitioner vs specialist). For each
group, we measured dose intensity, measured by pre-
scribed daily dose, and duration of colchicine use as
measured with the use of prescription start and stop dates
divided into the following categories: (1) r3 days, (2) 4
to 7 days, (3) 8 to 14 days, (4) 15 to 30 days,
(5) 31 to 60 days, (6) 61 to 90 days, (7) 91 to
180 days, and (8) 4181 days.
Multivariate logistic regression was performed to
identify predictors of NSSPP beneﬁciaries aged Z65
years making a claim for colchicine 490 and 4180
days. Potential predictors included the year colchicine
was initially prescribed, patient sex and age. All
analyses were performed with SAS/STAT software,
version 9.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
From April 1, 2006 to March 31, 2011, 903 unique
NSSPP beneﬁciaries met criteria for incident gout and
were dispensed drug therapy for management of gout as
deﬁned by our methods. Of these beneﬁciaries, 518
individuals were dispensed a total of 1327 courses of
colchicine between April 1, 2006 and March 31, 2011.
Baseline characteristics are summarized in Table I. The
majority (55.0%) in our study cohort were aged Z75
years at the date of their ﬁrst prescription for colchicine
and slightly more than one-half (50.2%) were women.
Most patients (92.5%) in our cohort were coded with a
diagnosis of gout by their general practitioner.
The mean (SD) prescribed daily dose of colchicine
received by NSSPP beneﬁciaries (including day 1 of
therapy) ranged from 1.39 (1.08) mg to 1.50 (1.02)
mg during the study period. Despite lower dosing
recommendations from EULAR and ACR, colchicine
doses 41.2 mg were prescribed in approximately
one-third of the study population in each ﬁscal year.
The proportion of treatment courses r1.2, r1.5,
and 41.5 mg/d by ﬁscal year is outlined in Table II.
The logistic model suggested that women were
signiﬁcantly less likely than men to be prescribed
colchicine for 490 continuous days, but age and the2341
Table I. Baseline characteristics of Nova Scotia
Seniors’ Pharmacare Program benefi-
ciaries receiving colchicine therapy.
Characteristic N %
Male 258 49.8
Female 260 50.2
Age, y*
65–69 120 23.2
70–74 113 21.8
75–79 116 22.4
80–84 90 17.4
Z85 79 15.3
*Age at date of ﬁrst prescription for colchicine.
Clinical Therapeuticsyear of the prescription were not signiﬁcant. None of
these factors were signiﬁcant in predicting 4180
days of continuous prescribing. Overall, the 90- and
180-day models correctly predicted 60% and 62% of
observed durations, respectively.
The majority (75.4%) of treatment courses were
prescribed for 47 days. The duration of colchicine use
by year on the basis of 14-day treatment gaps for r90
days, r180 days, 4180 days, and cumulative days of
colchicine use by ﬁscal year are outlined in Figures 1 and
2. Colchicine was prescribed for r90 days in 85.8% of
treatment courses and for r180 days in 91.9% of
treatment courses. A total of 8.1% of courses were
continued for 46 months. The proportion of beneﬁcia-
ries who received colchicine 490 days remained
consistent from 2006 to 2010 (14.1% vs 14.9%) despiteTable II. Colchicine dosing by calendar year (April 1,
Pharmacare Program beneficiaries.
Dose 2006 2007 2
r1.2 mg, no. (%) 86 (63.7) 145 (72.1) 175
r1.5 mg, no. (%) 94 (69.6) 148 (73.6) 180
41.5 mg, no. (%) 41 (30.4) 53 (26.4) 86
Total 135 201 266
Values may not sum 100% as patients in the ≤1.2 group may h
2342publication of initial recommendations from STOPP
criteria in 2008 which suggested prolonged use of
colchicine as potentially inappropriate. The proportion
of beneﬁciaries exceeding 4180 days also remained
consistent from 2006 to the end of 2010 (8.1% vs
9.8%). Women were signiﬁcantly less likely than men
to have a duration490 days, but, as shown in Table III,
no other factors were signiﬁcant predictors of having a
treatment duration 490 or 180 days.DISCUSSION
The mean prescribed daily dose (ranging from 1.39 to
1.50 mg from 2006 to 2011) exceeded current dosing
recommendations of 0.6 mg once or twice daily for
management of acute gout (after the initial dosing of 1.8
mg in the ﬁrst hour) and chronic gout.4 In addition, a
potentially concerning 27.9% to 38.7% of study
participants received 41.2 mg/d between April 1, 2006
and March 31, 2011. NSSPP beneﬁciary treatment
courses (14.2%) exceeded durations of 43 months and
8.1% of beneﬁciary treatment courses continued 46
months of prophylaxis despite the recommendation by
STOPP version 1 to avoid prolonged use of colchicine.
Despite publication of EULAR guidelines in 2006,
STOPP criteria in 2008, and the landmark trial by
Terkeltaub in 2010, no signiﬁcant change in colchicine
dosing or duration was observed over the course of the
study. Women were signiﬁcantly less likely to receive
longer durations of colchicine than men, suggesting men
are at greater risk of inappropriate duration of colchicine
use. However, the moderate ﬁt of the logistic models
suggested that other unobserved factors also had a
substantive impact on prescribing decisions.2006 to March 31, 2011) in Nova Scotia Seniors’
008 2009 2010 2011
(65.8) 199 (67.5) 206 (61.3) 63 (67.0)
(67.7) 206 (69.8) 213 (63.4) 65 (69.1)
(32.3) 89 (30.2) 123 (36.6) 29 (30.9)
295 336 94
ave also been captured in the ≤1.5 group.
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Figure 1. Proportion of Nova Scotia Seniors’ Pharmacare Program beneficiaries by cholchicine duration and
year.
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mg for 1 to 3 days, followed by 0.6 mg orally, is
Can$20 to Can$28 for a 30-day supply.21
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October 2015shorter durations has the potential for cost savings to
the NSSPP, private drug plans, and individual patients,
but any economic analysis must also account for the
health consequences of changing prescribing behaviors.210 240 270 300 330 360
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r year (April 1, 2006 to March 31, 2011) in Nova
ries for first treatment course per year.
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Table III. Patient descriptors and duration of
colchicine use (490 days and 4180
days) based on multivariate logistic
regression.
Colchicine Duration
490 days 4180 days
Per calendar year 0.967
(0.876–1.066)
1.021
(0.913–1.142)
Per 5-year increase
in age
1.083
(0.975–1.205)
1.029
(0.912–1.160)
Women (vs men) 0.737
(0.548–0.992)*
0.814
(0.580–1.142)
Values are expressed as odds ratio (95% CI).
*Signiﬁcant at 0.05 level.
Clinical TherapeuticsSuch an analysis was beyond the scope of this study,
but future work should examine the cost effectiveness
of implementing these guidelines.
Limited data on appropriateness of colchicine in
treatment of gout are reported in the literature. In a
study of hospitalized patients treated for acute gout,
26% were considered to be receiving an inappropriate
mean initial colchicine dose of 41.5 mg/d. Patients
who received higher mean doses and longer durations
of therapy had an increased risk of diarrhea.22
Although we were unable to differentiate between
acute and chronic gout, similarly in our study,
approximately one-quarter of patients with gout
received mean doses of colchicine 41.5 mg.
A retrospective review that evaluated colchicine
prescribing for prevention of acute gout in an out-
patient primary care setting reported inappropriate use
by 73.8% of the study population.23 Patients in that
study received lower mean doses of colchicine (0.6 mg/
d) as prophylaxis than our study population. However,
patients in both the appropriate and inappropriate
arms received extended durations of treatment
(median, 1.12 years and 3.26 years, respectively).23
Limited data support the optimal duration of colchicine
prophylaxis when initiated in combination with ULT to
prevent acute gout attacks; however, like a proportion
of patients in our study, patients in both appropriate
and inappropriate arms exceeded current ACR
guidelines and STOPP criteria recommendations for2344the duration of colchicine use.23 Extending treatment
durations may lead to continued risk of adverse effects,
a higher pill burden, and increased costs to patients or
the health care system.
Development of a protocol to guide treatment of gout
may improve adherence to guidelines and STOPP
criteria. Kamalaraj et al24 studied the effect of
implementing a protocol for the treatment of gout in
hospitalized patients. The protocol targeted non-
rheumatologists and was implemented with a variety
of formats, including wall posters depicting the protocol
in words, educational sessions led by rheumatologists,
and a link on the hospital’s intranet (triggered when a
serum urate concentration was ordered). Their results
found that 22.1% of patients in the preprotocol group
were prescribed inappropriate doses of colchicine (41.5
mg/d) compared with only 1.5% of patients in the post-
protocol group (P o 0.001). The number of adverse
events also decreased from 28% before the protocol to
13.5% after the protocol (P o 0.01).24 In that study,
approximately one-quarter of patients were prescribed
high-dose colchicine by non-rheumatologists.
Implementing simple, evidence-based clinical deci-
sion support tools for colchicine dose and duration
through information technology used by general prac-
titioners may be an additional strategy to improving
practice.25–27 Clinical decision support tools, which
include information on recommended colchicine dose
and duration, could be incorporated into electronic
health records used by general practitioners. The more
speciﬁc and directed the tool is, the more successful the
intervention in affecting prescribing behaviors.28
Our study has several strengths. It provides 5-year
data of a large population. As recommended by
Johnson et al,29 we implemented incident user
design, which identiﬁed patients who were newly
prescribed medications for management of gout.
This strategy minimizes bias that results from
comparisons of new patients with patients who have
been on the medication before the start of the study
and captures all events that occurred after the
initiation of treatment.29
A number of limitations should be considered. The
NSSPP data include only beneﬁciaries eligible and
registered in the program and does not capture data
for patients aged Z65 years who may pay out of
pocket or are covered by private drug insurance
companies. It does not separately report on the
7.5% of the population who reside in long-termVolume 37 Number 10
E. Black et al.care. In addition, administrative prescription data
were not linked to other health records or patient
reported outcomes, and we are limited in our ability to
identify the type and clinical characteristics of gout or
to follow patients to monitor beneﬁt or harm. We
were also unable to determine contraindications to
ULT or nonsteroidal anti-inﬂammatory drugs, which
may require lengths of colchicine therapy 46
months.2 Other limitations include an inability to
determine use of colchicine through prescription
drug samples or to identify patients for whom the
drug was prescribed and not dispensed. Finally,
we were unable to assess patient adherence to
recommended therapy.
Generalizability of results should also be considered.
Almost one-half of our study population were women;
however, gout has been shown to occur more com-
monly in men than women in the general population. In
those aged 70 to 79 years, population estimates report
that 10.8% of men compared with 4.6% of women
have experienced gout.1 Despite these limitations, our
results provide insight into prescribing practices of
physicians for management of gout in older persons.CONCLUSIONS
Our ﬁndings are the ﬁrst to report on colchicine dose
and duration with the use of STOPP criteria in a
speciﬁc cohort of older persons with incident gout. At
the end of the study period, the number of older
persons dispensed potentially inappropriate colchicine
doses (41.2 mg/d) and extended durations (43
months) remained high (27.9%–38.7% per year and
14.2%, respectively) despite new evidence. Academic
detailing programs and clinical decision support tools
directed to general practitioners and other prescribers
are needed to improve colchicine dosing and duration.
Future research should focus on evaluation of imple-
mented interventions and completion of real-world
studies to examine the optimal length for prophylactic
use of colchicine so patients are not continued on
therapy indeﬁnitely. Finally, appropriate use of col-
chicine may result in cost savings to insurers and
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